サンプル依頼リスト カート
  • English
  • Korean
  • Traditional Chinese
  • Simplified Chinese
デフォルト表紙
市場調査レポート
商品コード
1363243

吸入薬の市場規模、シェア、動向分析レポート：薬剤クラス別、用途別、地域別、セグメント別予測、2023年～2030年

Inhalable Drugs Market Size, Share & Trends Analysis Report By Drug Class (Aerosol, Dry Powder Formulation, Spray), By Application (Respiratory & Non-Respiratory Diseases), By Region, And Segment Forecasts, 2023 - 2030
出版日: | 発行: Grand View Research | ページ情報: 英文 80 Pages | 納期: 2～10営業日

● お客様のご希望に応じて、既存データの加工や未掲載情報（例：国別セグメント）の追加などの対応が可能です。　 詳細はお問い合わせください。

価格
価格表記: USDを日本円(税抜)に換算
本日の銀行送金レート: 1USD=156.76円
吸入薬の市場規模、シェア、動向分析レポート：薬剤クラス別、用途別、地域別、セグメント別予測、2023年～2030年
出版日: 2023年09月26日
発行: Grand View Research
ページ情報: 英文 80 Pages
納期: 2～10営業日
  • 全表示
  • 概要
  • 図表
  • 目次
概要

吸入薬市場の成長と動向：

Grand View Research, Inc.の最新レポートによると、世界の吸入薬市場規模は2030年までに524億米ドル以上に達し、2023年から2030年までのCAGRは6.6％を記録する見込みです。

呼吸器疾患の有病率の上昇と高齢人口の増加は、市場を牽引すると予想される主要因の一部です。慢性閉塞性肺疾患（COPD）は生命を脅かす呼吸器疾患で、世界的に死因の第3位になると予測されています。このため、吸入可能な薬剤の需要が増加します。

Global Burden of Disease調査によると、2016年には世界で2億5100万人のCOPD患者が報告されました。それゆえ、吸入可能な新薬を開発する必要性が高まっています。例えば、2019年1月、Verona PharmaはCOPDを適応症とするEnsifentrineの開発でWHOの承認を受け、臨床試験のフェーズIIを完了しました。

吸入薬の進歩は、吸入薬市場を推進すると予想されます。ナノ粒子は、先進的な吸入薬の開発のために研究されています。例えば、2019年4月、クイーンズランド工科大学の科学者は、肺がんの吸入粉末を装填したキトサンナノ粒子を用いた調査を実施しました。これらのナノ粒子は下気道を容易に透過し、血流に拡散することができます。

糖尿病やパーキンソン病などの非呼吸器疾患の有病率の上昇も市場を牽引すると予想されます。そのため、メーカーは費用対効果の高い革新的な吸入式薬剤を開発しています。例えば、2019年1月、MannKind Corporationは糖尿病患者向けのAfrezzaを開発し、商品化しました。

強力なパイプライン医薬品の存在は、市場成長を後押しすると推定される主要因の1つと考えられています。臨床試験中のプロジェクトは世界全体で220以上あります。例えば、グラクソ・スミスクライン社の喘息治療薬Fluticasone Furoate/Vilanterol/Umeclidinium Bromideの3剤併用療法はフェーズIII段階にあり、予測期間中に上市される可能性が高いです。

企業は、製品ポートフォリオを拡大し、市場でより強固な足場を得るために、提携、M&A、パートナーシップ、認知度向上プログラムなどの戦略的イニシアチブをとっています。例えば、2019年7月、Cipla, Inc.は上海を拠点とするJiangsu Acebright Pharmaceuticalsと合弁会社を設立し、中華人民共和国に呼吸器製品を製造する会社を設立しました。

吸入薬市場レポートハイライト

  • 製品別では、密度が低く吸入器で容易に分散できるなどの利点から、乾燥粉末製剤セグメントが2022年の吸入薬市場を独占しました。
  • 用途別では、喘息やCOPDの有病率の高さから、2022年には呼吸器疾患が収益面で最大の市場シェアを占めました。非呼吸器疾患セグメントは、様々な神経疾患の管理における高い機会のため、急速なペースで成長しています。
  • 北米は、確立された製薬業界やヘルスケア施設、吸入器の使用に関する意識の高まりに牽引され、2022年の吸入薬の世界市場で主導的地位を占めました。アジア太平洋市場は予測期間中に最も速い成長を示すと予測されています。
  • この業界の主要企業には、アストラゼネカ、ベクチュラ、シプラ社、グラクソ・スミスクライン、ノバルティス、ムンディファーマ、ベーリンガー・インゲルハイム・インターナショナル社、マイランなどがあります。

目次

第1章 調査手法と範囲

第2章 エグゼクティブサマリー

第3章 吸入薬市場の変数、動向、範囲

  • 市場系統の見通し
    • 親市場の見通し
    • 関連/付随市場の見通し
  • 普及と成長の見通しマッピング
  • 市場力学
    • 市場促進要因分析
    • 市場抑制要因分析
  • 吸入薬市場分析ツール
    • 業界分析- ポーターのファイブフォース分析
    • PESTEL分析

第4章 吸入薬：薬剤クラスの推定・動向分析

  • 吸入薬市場：重要なポイント
  • 吸入薬市場：動向と市場シェア分析、2022年および2030年
  • エアロゾル
  • ドライパウダー製剤
  • スプレー

第5章 吸入薬：用途の推定・動向分析

  • 吸入薬市場：重要なポイント
  • 吸入薬市場：動向と市場シェア分析、2022年および2030年
  • 呼吸器疾患
  • 非呼吸器疾患

第6章 吸入薬市場：地域の推定・動向分析

  • 地域別の見通し
  • 地域別の吸入薬市場：重要なポイント
  • 北米
    • 市場推計・予測、2018～2030年
    • 米国
    • カナダ
  • 欧州
    • 英国
    • ドイツ
    • フランス
    • イタリア
    • スペイン
    • デンマーク
    • スウェーデン
    • ノルウェー
  • アジア太平洋地域
    • 日本
    • 中国
    • インド
    • オーストラリア
    • タイ
    • 韓国
  • ラテンアメリカ
    • ブラジル
    • メキシコ
    • アルゼンチン
  • 中東・アフリカ
    • 南アフリカ
    • サウジアラビア
    • アラブ首長国連邦
    • クウェート

第7章 競合情勢

  • 主要市場参入企業による最近の動向と影響分析
  • 市場参入企業の分類
    • AstraZeneca
    • Sanofi
    • Vectura Group Ltd
    • Viatris Inc.
    • GSK plc.
    • Mundipharma International.
    • Boehringer Ingelheim International GmbH.
    • Cipla Inc.
図表

List of Tables

  • Table 1 List of Abbreviation
  • Table 2 North America inhalable drugs market, by drug class, 2018 - 2030 (USD Million)
  • Table 3 North America inhalable drugs market, by application, 2018 - 2030 (USD Million)
  • Table 4 North America inhalable drugs market, by region, 2018 - 2030 (USD Million)
  • Table 5 U.S. inhalable drugs market, by drug class, 2018 - 2030 (USD Million)
  • Table 6 U.S. inhalable drugs market, by application, 2018 - 2030 (USD Million)
  • Table 7 Canada inhalable drugs market, by drug class, 2018 - 2030 (USD Million)
  • Table 8 Canada inhalable drugs market, by application, 2018 - 2030 (USD Million)
  • Table 9 Europe inhalable drugs market, by drug class, 2018 - 2030 (USD Million)
  • Table 10 Europe inhalable drugs market, by application, 2018 - 2030 (USD Million)
  • Table 11 Europe inhalable drugs market, by region, 2018 - 2030 (USD Million)
  • Table 12 Germany inhalable drugs market, by drug class, 2018 - 2030 (USD Million)
  • Table 13 Germany inhalable drugs market, by application, 2018 - 2030 (USD Million)
  • Table 14 UK inhalable drugs market, by drug class, 2018 - 2030 (USD Million)
  • Table 15 UK inhalable drugs market, by application, 2018 - 2030 (USD Million)
  • Table 16 France inhalable drugs market, by drug class, 2018 - 2030 (USD Million)
  • Table 17 France inhalable drugs market, by application, 2018 - 2030 (USD Million)
  • Table 18 Italy inhalable drugs market, by drug class, 2018 - 2030 (USD Million)
  • Table 19 Italy inhalable drugs market, by application, 2018 - 2030 (USD Million)
  • Table 20 Spain inhalable drugs market, by drug class, 2018 - 2030 (USD Million)
  • Table 21 Spain inhalable drugs market, by application, 2018 - 2030 (USD Million)
  • Table 22 Denmark inhalable drugs market, by drug class, 2018 - 2030 (USD Million)
  • Table 23 Denmark inhalable drugs market, by application, 2018 - 2030 (USD Million)
  • Table 24 Sweden inhalable drugs market, by drug class, 2018 - 2030 (USD Million)
  • Table 25 Sweden inhalable drugs market, by application, 2018 - 2030 (USD Million)
  • Table 26 Norway inhalable drugs market, by drug class, 2018 - 2030 (USD Million)
  • Table 27 Norway inhalable drugs market, by application, 2018 - 2030 (USD Million)
  • Table 28 Asia Pacific inhalable drugs market, by drug class, 2018 - 2030 (USD Million)
  • Table 29 Asia Pacific inhalable drugs market, by application, 2018 - 2030 (USD Million)
  • Table 30 Asia Pacific inhalable drugs market, by region, 2018 - 2030 (USD Million)
  • Table 31 Japan inhalable drugs market, by drug class, 2018 - 2030 (USD Million)
  • Table 32 Japan inhalable drugs market, by application, 2018 - 2030 (USD Million)
  • Table 33 China inhalable drugs market, by drug class, 2018 - 2030 (USD Million)
  • Table 34 China inhalable drugs market, by application, 2018 - 2030 (USD Million)
  • Table 35 India inhalable drugs market, by drug class, 2018 - 2030 (USD Million)
  • Table 36 India inhalable drugs market, by application, 2018 - 2030 (USD Million)
  • Table 37 Australia inhalable drugs market, by drug class, 2018 - 2030 (USD Million)
  • Table 38 Australia inhalable drugs market, by application, 2018 - 2030 (USD Million)
  • Table 39 Thailand inhalable drugs market, by drug class, 2018 - 2030 (USD Million)
  • Table 40 Thailand inhalable drugs market, by application, 2018 - 2030 (USD Million)
  • Table 41 South Korea inhalable drugs market, by drug class, 2018 - 2030 (USD Million)
  • Table 42 South Korea inhalable drugs market, by application, 2018 - 2030 (USD Million)
  • Table 43 Latin America inhalable drugs market, by drug class, 2018 - 2030 (USD Million)
  • Table 44 Latin America inhalable drugs market, by application, 2018 - 2030 (USD Million)
  • Table 45 Latin America inhalable drugs market, by region, 2018 - 2030 (USD Million)
  • Table 46 Brazil inhalable drugs market, by drug class, 2018 - 2030 (USD Million)
  • Table 47 Brazil inhalable drugs market, by application, 2018 - 2030 (USD Million)
  • Table 48 Mexico inhalable drugs market, by drug class, 2018 - 2030 (USD Million)
  • Table 49 Mexico inhalable drugs market, by application, 2018 - 2030 (USD Million)
  • Table 50 Argentina inhalable drugs market, by drug class, 2018 - 2030 (USD Million)
  • Table 51 Argentina inhalable drugs market, by application, 2018 - 2030 (USD Million)
  • Table 52 Middle East and Africa inhalable drugs market, by drug class, 2018 - 2030 (USD Million)
  • Table 53 Middle East and Africa inhalable drugs market, by application, 2018 - 2030 (USD Million)
  • Table 54 Middle East and Africa inhalable drugs market, by region, 2018 - 2030 (USD Million)
  • Table 55 South Africa inhalable drugs market, by drug class, 2018 - 2030 (USD Million)
  • Table 56 South Africa inhalable drugs market, by application, 2018 - 2030 (USD Million)
  • Table 57 Saudi Arabia inhalable drugs market, by drug class, 2018 - 2030 (USD Million)
  • Table 58 Saudi Arabia inhalable drugs market, by application, 2018 - 2030 (USD Million)
  • Table 59 UAE inhalable drugs market, by drug class, 2018 - 2030 (USD Million)
  • Table 60 UAE inhalable drugs market, by application, 2018 - 2030 (USD Million)
  • Table 61 Kuwait inhalable drugs market, by drug class, 2018 - 2030 (USD Million)
  • Table 62 Kuwait inhalable drugs market, by Application, 2018 - 2030 (USD Million)

List of Figures

  • Fig. 1 Market research process
  • Fig. 2 Data triangulation techniques
  • Fig. 3 Primary research pattern
  • Fig. 4 Market research approaches
  • Fig. 5 Value-chain-based sizing & forecasting
  • Fig. 6 QFD modeling for market share assessment
  • Fig. 7 Market formulation & validation
  • Fig. 8 Inhalable drugs: Market outlook
  • Fig. 9 Inhalable drugs: Competitive insights
  • Fig. 10 Parent market outlook
  • Fig. 11 Related/ancillary market outlook
  • Fig. 12 Penetration and growth prospect mapping
  • Fig. 13 Industry value chain analysis
  • Fig. 14 Inhalable drugs market driver impact
  • Fig. 15 Inhalable drugs market restraint impact
  • Fig. 16 Inhalable drugs market strategic initiatives analysis
  • Fig. 17 Inhalable drugs market: Drug class movement analysis
  • Fig. 18 Inhalable drugs market: Drug class outlook and key takeaways
  • Fig. 19 Aerosol market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 20 Dry powder formulation market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 21 Spray market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 22 Inhalable drugs market: Application movement analysis
  • Fig. 23 Inhalable drugs market: Application outlook and key takeaways
  • Fig. 24 Respiratory diseases market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 25 Non-respiratory diseases market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 26 Global inhalable drugs market: Regional movement analysis
  • Fig. 27 Global inhalable drugs market: Regional outlook and key takeaways
  • Fig. 28 North America market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 29 U.S. market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 30 Canada market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 31 Europe market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 32 UK market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 33 Germany market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 34 France market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 35 Italy market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 36 Spain market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 37 Sweden market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 38 Norway market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 39 Denmark market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 40 Asia Pacific market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 41 Japan market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 42 China market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 43 India market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 44 Australia market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 45 Thailand market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 46 South Korea market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 47 Latin America market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 48 Brazil market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 49 Mexico market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 50 Argentina market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 51 Middle East and Africa. market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 52 Saudi Arabia market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 53 South Africa market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 54 UAE market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 55 Kuwait market estimates and forecasts, 2018 - 2030 (USD Million)
目次
Product Code: GVR-3-68038-767-4

Inhalable Drugs Market Growth & Trends:

The global inhalable drugs market size is expected to reach over USD 52.4 billion by 2030, according to a new report by Grand View Research, Inc.., registering a CAGR of 6.6% from 2023 to 2030. Rising prevalence of respiratory diseases and increasing geriatric population are some of the key factors expected to drive the market. Chronic obstructive pulmonary disease (COPD) is a life-threatening respiratory ailments, which is projected to become the third leading cause of death globally. This will increase the demand for inhalable drugs.

According to the Global Burden of Disease study, in 2016, 251 million cases of COPD were reported worldwide. Hence, the need for developing new inhalable drugs has increased. For instance, in January 2019, Verona Pharma received WHO approval for developing Ensifentrine indicated for COPD, which has completed Phase II of clinical trials.

Advancements in inhalable drugs is anticipated to propel the inhalable drugsmarket. Nanoparticles are studied for the development of advanced inhalation drugs. For instance, in April 2019, a scientist from Queensland University of Technology conducted a research using chitosan nanoparticles loaded with inhalation powder for lung cancer. These nanoparticles can easily penetrate the lower respiratory tract and can diffuse into the bloodstream.

Rising prevalence of non-respiratory diseases such as diabetes and Parkinson's diseases is also expected to drive the market. Therefore, manufacturers are developing cost-effective and innovative inhalable drugs. For instance, in January 2019, MannKind Corporation developed and commercialized Afrezza for diabetic patients.

Presence of strong pipeline drugs is considered to be one of the major factors estimated to boost the market growth. There are more than 220 ongoing projects under clinical trials globally. For instance, GlaxoSmithKline's triple combination therapy of Fluticasone Furoate/Vilanterol/Umeclidinium Bromide to treat asthma is in Phase III and is likely to be launched during the forecast period.

Companies are undergoing strategic initiatives such as collaborations, mergers and acquisitions, partnerships, and awareness programs to widen their product portfolio and gain a stronger foothold in the market. For instance, in July 2019, Cipla, Inc. entered into a joint venture with Shanghai-based Jiangsu Acebright Pharmaceuticals to establish a company in the People's Republic of China to manufacture respiratory products.

Inhalable Drugs Market Report Highlights:

  • By product, the dry powder formulation segment dominated the market for inhalable drugs in 2022 owing to benefits such as low density and ability to disperse easily through inhalers
  • Based on application, respiratory diseases held the largest market share in terms of revenue in 2022, due to high prevalence of asthma and COPD. The non-respiratory diseases segment is growing at a rapid pace owing to the high opportunity in management of various neurological disorders
  • North America held the leading position in the global inhalable drugs market for inhalable drugs in 2022, driven by established pharmaceutical industry and healthcare facilities and growing awareness about the use of inhalers. The Asia Pacific market is projected to exhibit the fastest growth during the forecast period.
  • Key players in this industry include AstraZeneca; Vectura, Cipla Inc.; GlaxoSmithKline; Novartis; Mundipharma; Boehringer Ingelheim International GmbH; and Mylan.

Table of Contents

Chapter 1. Methodology and Scope

  • 1.1. Market Segmentation & Scope
    • 1.1.1. Drug Class
    • 1.1.2. Application
    • 1.1.3. Regional scope
    • 1.1.4. Estimates and forecast timeline
  • 1.2. Research Methodology
  • 1.3. Information Procurement
    • 1.3.1. Purchased database
    • 1.3.2. GVR's internal database
    • 1.3.3. Secondary sources
    • 1.3.4. Primary research
    • 1.3.5. Details of primary research
  • 1.4. Information or Data Analysis
  • 1.5. Market Formulation & Validation
  • 1.6. Model Details
  • 1.7. List of Secondary Sources
  • 1.8. List of Primary Sources
  • 1.9. Objectives

Chapter 2. Executive Summary

  • 2.1. Market Outlook
  • 2.2. Segment Outlook
    • 2.2.1. Drug class outlook
    • 2.2.2. Application outlook
    • 2.2.3. Regional outlook
  • 2.3. Competitive Insights

Chapter 3. Inhalable Drugs Market Variables, Trends & Scope

  • 3.1. Market Lineage Outlook
    • 3.1.1. Parent market outlook
    • 3.1.2. Related/ancillary market outlook
  • 3.2. Penetration & Growth Prospect Mapping
  • 3.3. Market Dynamics
    • 3.3.1. Market driver analysis
    • 3.3.2. Market restraint analysis
  • 3.4. Inhalable Drugs Market Analysis Tools
    • 3.4.1. Industry Analysis - Porter's
      • 3.4.1.1. Supplier power
      • 3.4.1.2. Buyer power
      • 3.4.1.3. Substitution threat
      • 3.4.1.4. Threat of new entrant
      • 3.4.1.5. Competitive rivalry
    • 3.4.2. PESTEL Analysis
      • 3.4.2.1. Political landscape
      • 3.4.2.2. Technological landscape
      • 3.4.2.3. Economic landscape

Chapter 4. Inhalable Drugs: Drug Class Estimates & Trend Analysis

  • 4.1. Inhalable Drugs Market: Key Takeaways
  • 4.2. Inhalable Drugs Market: Movement & Market Share Analysis, 2022 & 2030
  • 4.3. Aerosol
    • 4.3.1. Aerosol market estimates and forecasts, 2018 to 2030 (USD Million)
  • 4.4. Dry Powder Formulation
    • 4.4.1. Dry powder formulation market estimates and forecasts, 2018 to 2030 (USD Million)
  • 4.5. Spray
    • 4.5.1. Spray market estimates and forecasts, 2018 to 2030 (USD Million)

Chapter 5. Inhalable Drugs: Application Estimates & Trend Analysis

  • 5.1. Inhalable Drugs Market: Key Takeaways
  • 5.2. Inhalable Drugs Market: Movement & Market Share Analysis, 2022 & 2030
  • 5.3. Respiratory Diseases
    • 5.3.1. Respiratory diseases market estimates and forecasts, 2018 to 2030 (USD Million)
  • 5.4. Non-respiratory Diseases
    • 5.4.1. Non-respiratory diseases market estimates and forecasts, 2018 to 2030 (USD Million)

Chapter 6. Inhalable Drugs Market: Regional Estimates & Trend Analysis

  • 6.1. Regional Outlook
  • 6.2. Inhalable Drugs Market by Region: Key Takeaways
  • 6.3. North America
    • 6.3.1. Market estimates and forecasts, 2018 - 2030 (Revenue, USD Million)
    • 6.3.2. U.S.
      • 6.3.2.1. Market estimates and forecasts, 2018 - 2030 (Revenue, USD Million)
    • 6.3.3. Canada
      • 6.3.3.1. Market estimates and forecasts, 2018 - 2030 (Revenue, USD Million)
  • 6.4. Europe
    • 6.4.1. UK
      • 6.4.1.1. Market estimates and forecasts, 2018 - 2030 (Revenue, USD Million)
    • 6.4.2. Germany
      • 6.4.2.1. Market estimates and forecasts, 2018 - 2030 (Revenue, USD Million)
    • 6.4.3. France
      • 6.4.3.1. Market estimates and forecasts, 2018 - 2030 (Revenue, USD Million)
    • 6.4.4. Italy
      • 6.4.4.1. Market estimates and forecasts, 2018 - 2030 (Revenue, USD Million)
    • 6.4.5. Spain
      • 6.4.5.1. Market estimates and forecasts, 2018 - 2030 (Revenue, USD Million)
    • 6.4.6. Denmark
      • 6.4.6.1. Market estimates and forecasts, 2018 - 2030 (Revenue, USD Million)
    • 6.4.7. Sweden
      • 6.4.7.1. Market estimates and forecasts, 2018 - 2030 (Revenue, USD Million)
    • 6.4.8. Norway
      • 6.4.8.1. Market estimates and forecasts, 2018 - 2030 (Revenue, USD Million)
  • 6.5. Asia Pacific
    • 6.5.1. Japan
      • 6.5.1.1. Market estimates and forecasts, 2018 - 2030 (Revenue, USD Million)
    • 6.5.2. China
      • 6.5.2.1. Market estimates and forecasts, 2018 - 2030 (Revenue, USD Million)
    • 6.5.3. India
      • 6.5.3.1. Market estimates and forecasts, 2018 - 2030 (Revenue, USD Million)
    • 6.5.4. Australia
      • 6.5.4.1. Market estimates and forecasts, 2018 - 2030 (Revenue, USD Million)
    • 6.5.5. Thailand
      • 6.5.5.1. Market estimates and forecasts, 2018 - 2030 (Revenue, USD Million)
    • 6.5.6. South Korea
      • 6.5.6.1. Market estimates and forecasts, 2018 - 2030 (Revenue, USD Million)
  • 6.6. Latin America
    • 6.6.1. Brazil
      • 6.6.1.1. Market estimates and forecasts, 2018 - 2030 (Revenue, USD Million)
    • 6.6.2. Mexico
      • 6.6.2.1. Market estimates and forecasts, 2018 - 2030 (Revenue, USD Million)
    • 6.6.3. Argentina
      • 6.6.3.1. Market estimates and forecasts, 2018 - 2030 (Revenue, USD Million)
  • 6.7. MEA
    • 6.7.1. South Africa
      • 6.7.1.1. Market estimates and forecasts, 2018 - 2030 (Revenue, USD Million)
    • 6.7.2. Saudi Arabia
      • 6.7.2.1. Market estimates and forecasts, 2018 - 2030 (Revenue, USD Million)
    • 6.7.3. UAE
      • 6.7.3.1. Market estimates and forecasts, 2018 - 2030 (Revenue, USD Million)
    • 6.7.4. Kuwait
      • 6.7.4.1. Market estimates and forecasts, 2018 - 2030 (Revenue, USD Million)

Chapter 7. Competitive Landscape

  • 7.1. Recent Developments & Impact Analysis, By Key Market Participants
  • 7.2. Market Participant Categorization
    • 7.2.1. AstraZeneca
      • 7.2.1.1. Company overview
      • 7.2.1.2. Financial performance
      • 7.2.1.3. Product benchmarking
      • 7.2.1.4. Strategic initiatives
    • 7.2.2. Sanofi
      • 7.2.2.1. Company overview
      • 7.2.2.2. Financial performance
      • 7.2.2.3. Product benchmarking
      • 7.2.2.4. Strategic initiatives
    • 7.2.3. Vectura Group Ltd
      • 7.2.3.1. Company overview
      • 7.2.3.2. Financial performance
      • 7.2.3.3. Product benchmarking
      • 7.2.3.4. Strategic initiatives
    • 7.2.4. Viatris Inc.
      • 7.2.4.1. Company overview
      • 7.2.4.2. Financial performance
      • 7.2.4.3. Product benchmarking
      • 7.2.4.4. Strategic initiatives
    • 7.2.5. GSK plc.
      • 7.2.5.1. Company overview
      • 7.2.5.2. Financial performance
      • 7.2.5.3. Product benchmarking
      • 7.2.5.4. Strategic initiatives
    • 7.2.6. Mundipharma International.
      • 7.2.6.1. Company overview
      • 7.2.6.2. Financial performance
      • 7.2.6.3. Product benchmarking
      • 7.2.6.4. Strategic initiatives
    • 7.2.7. Boehringer Ingelheim International GmbH.
      • 7.2.7.1. Company overview
      • 7.2.7.2. Financial performance
      • 7.2.7.3. Product benchmarking
      • 7.2.7.4. Strategic initiatives
    • 7.2.8. Cipla Inc.
      • 7.2.8.1. Company overview
      • 7.2.8.2. Financial performance
      • 7.2.8.3. Product benchmarking
      • 7.2.8.4. Strategic initiatives